<DOC>
	<DOCNO>NCT02074553</DOCNO>
	<brief_summary>This 2-part , single center , open-label , randomize , single-dose , 4-sequence , 4-period cross-over study compare bioequivalence three test alectinib capsule formulation reference capsule formulation healthy adult participant . All participant fast ( Part 1 ) fed ( Part 2 ) condition study receive 4 treatment : Treatment A ( alectinib 50 percent [ % ] sodium lauryl sulfate [ SLS ] [ reference ] ) , Treatment B ( alectinib 25 % SLS [ test ] ) , Treatment C ( alectinib 12.5 % SLS [ test ] ) , Treatment D ( alectinib 3 % SLS [ test ] ) randomize sequence . Each treatment give single 600 milligram ( mg ) oral administration upright position Day 1 fed fast condition , follow 10-day washout period .</brief_summary>
	<brief_title>A Study Examining Bioequivalence 3 Alectinib ( RO5424802 ) Test Formulations Reference Formulation Healthy Participants</brief_title>
	<detailed_description />
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<criteria>Healthy male female participant . Healthy status define absence evidence active chronic disease follow detailed medical surgical history , complete physical examination Body mass index 18 32 kilogram per metersquared ( kg/m^2 ) inclusive Nonsmoking participant former smoking participant smoke past 6 month first study drug dose Female participant must surgically sterile postmenopausal past year Male participant partner childbearing potential must willing use two effective method contraception , one must barrier method ( example , condom ) study 90 day last drug administration Willing abstain xanthinecontaining beverage food ( coffee , tea , cola , chocolate , `` energy drink '' ) 72 hour prior Day 1 study end Willing abstain grapefruit , pomelo , star fruit , Seville orangecontaining product day 7 prior study start study end Willing avoid prolong sun exposure take alectinib followup Women childbearing potential , pregnant lactate woman , male female partner pregnant lactate Clinically significant abnormality physical examination , vital sign , laboratory test result screen prior admission study center Positive test drug abuse , alcohol , cotinine screen prior admission study center suspicion regular consumption drug ( ) abuse include marijuana History ( within 3 month Screening ) alcohol consumption exceed 2 standard drink per day average ( 1 standard drink = 10 gram [ g ] alcohol ) . Alcohol consume prohibit 72 hour prior study start end study Participants risk factor family history QT/Fridericia 's correct QT interval ( QTcF ) prolongation electrocardiogram abnormalities A history concurrent clinically significant hematologic , renal , hepatic , pulmonary , neurological , psychiatric , allergy , gastrointestinal , metabolic endocrine disorder , cardiovascular disease infection Positive screen test hepatitis B , C , human immunodeficiency virus ( HIV ) Use medication ( prescription overthecounter ) , within 2 week 5 halflives ( whichever longer ) first dose study drug exception acetaminophen 2 g per day 48 hour prior dose , exceed 4 g total week prior dose Routine chronic use 2 g acetaminophen daily Use herbal supplement ( example , St. John 's Wort ) metabolic inducer within 4 week 5 halflives ( whichever longer ) first dose study drug , include limited follow drug : rifampin , rifabutin , glucocorticoid , carbamazepine , phenytoin , phenobarbital Strenuous activity , sunbathe contact sport allow 4 day prior study start end study Participation investigational drug device study within 45 day 5 halflives ( whichever time period longer ) , 6 month biologic therapy , prior first study drug dose Donation blood 450 milliliter within 45 day prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>